

TN05 Anti-CD20 Specimen Inventory Summary by Treatment Arm and by Responder Status

Current to 2/22/2011

| Study Time Point | Treatment | | | | | | | | | | Placebo | | | | | | | | | |
|------------------|------------------|-----------------|------------------|-----------------|-------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|-------------------|-----------------|------------------|-----------------|------------------|-----------------|
| | PBMC | | Plasma | | Whole Blood - DNA | | RNA | | Serum (BAA) | | PBMC | | Plasma | | Whole Blood - DNA | | RNA | | Serum (BAA) | |
| | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples |
| Screening | 0 | 0 | 0 | 0 | 54 | 54 | 0 | 0 | 39 | 39 | 0 | 0 | 27 | 27 | 0 | 0 | 20 | 20 | 0 | 0 |
| Baseline | 50 | 184 | 55 | 581 | 1 | 1 | 34 | 249 | 0 | 0 | 28 | 102 | 28 | 283 | 1 | 1 | 15 | 94 | 0 | 0 |
| 5 weeks | 53 | 239 | 53 | 517 | 0 | 0 | 0 | 0 | 52 | 52 | 28 | 136 | 27 | 269 | 0 | 0 | 0 | 0 | 26 | 26 |
| 12 weeks | 51 | 179 | 52 | 500 | 0 | 0 | 0 | 0 | 37 | 37 | 29 | 126 | 30 | 298 | 0 | 0 | 0 | 0 | 21 | 21 |
| 26 weeks | 51 | 254 | 51 | 506 | 0 | 0 | 32 | 221 | 38 | 38 | 30 | 159 | 29 | 283 | 0 | 0 | 13 | 81 | 24 | 24 |
| 39 weeks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 23 |
| 52 weeks | 48 | 150 | 49 | 478 | 0 | 0 | 32 | 269 | 40 | 40 | 26 | 106 | 28 | 277 | 0 | 0 | 13 | 109 | 25 | 25 |
| 56 weeks | 2 | 4 | 2 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| 78 weeks | 42 | 210 | 44 | 422 | 0 | 0 | 27 | 237 | 43 | 43 | 27 | 143 | 27 | 257 | 0 | 0 | 16 | 145 | 24 | 24 |
| 104 weeks | 41 | 247 | 41 | 395 | 0 | 0 | 30 | 179 | 47 | 47 | 28 | 145 | 27 | 302 | 0 | 0 | 17 | 109 | 27 | 27 |
| 30 months | 8 | 44 | 10 | 100 | 0 | 0 | 9 | 26 | 41 | 41 | 5 | 27 | 5 | 45 | 0 | 0 | 4 | 15 | 23 | 23 |
| 36 months | 0 | 0 | 3 | 30 | 0 | 0 | 3 | 14 | 35 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 |
| 42 months | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 |
| 48 months | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |

| Study Time Point | Responder | | | | | | | | | | Non-Responder | | | | | | | | | |
|------------------|------------------|-----------------|------------------|-----------------|-------------------|-----------------|------------------|-----------------|----------------------|-----------------|------------------|-----------------|------------------|-----------------|-------------------|-----------------|------------------|-----------------|----------------------|-----------------|
| | PBMC | | Plasma | | Whole Blood - DNA | | RNA | | Serum (Residual BAA) | | PBMC | | Plasma | | Whole Blood - DNA | | RNA | | Serum (Residual BAA) | |
| | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples | Total # Subjects | Total # Samples |
| Screening | 0 | 0 | 0 | 0 | 40 | 40 | 0 | 0 | 34 | 34 | 0 | 0 | 0 | 0 | 34 | 34 | 0 | 0 | 23 | 23 |
| Baseline | 39 | 137 | 43 | 467 | 1 | 1 | 28 | 218 | 0 | 0 | 35 | 126 | 36 | 358 | 1 | 1 | 20 | 121 | 0 | 0 |
| 5 weeks | 44 | 194 | 43 | 420 | 0 | 0 | 0 | 0 | 41 | 41 | 35 | 172 | 35 | 346 | 0 | 0 | 0 | 0 | 35 | 35 |
| 12 weeks | 41 | 142 | 42 | 401 | 0 | 0 | 0 | 0 | 31 | 31 | 37 | 155 | 38 | 377 | 0 | 0 | 0 | 0 | 25 | 25 |
| 26 weeks | 44 | 231 | 43 | 423 | 0 | 0 | 26 | 181 | 36 | 36 | 37 | 182 | 37 | 366 | 0 | 0 | 19 | 121 | 26 | 26 |
| 39 weeks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 34 |
| 52 weeks | 41 | 134 | 41 | 401 | 0 | 0 | 25 | 210 | 35 | 35 | 33 | 122 | 36 | 354 | 0 | 0 | 20 | 168 | 29 | 29 |
| 56 weeks | 2 | 4 | 2 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| 78 weeks | 34 | 170 | 36 | 342 | 0 | 0 | 22 | 194 | 35 | 35 | 35 | 183 | 35 | 337 | 0 | 0 | 21 | 188 | 31 | 31 |
| 104 weeks | 37 | 179 | 37 | 341 | 0 | 0 | 25 | 151 | 40 | 40 | 31 | 207 | 30 | 346 | 0 | 0 | 21 | 135 | 33 | 33 |
| 30 months | 7 | 37 | 6 | 60 | 0 | 0 | 6 | 22 | 34 | 34 | 6 | 64 | 9 | 85 | 0 | 0 | 7 | 19 | 29 | 29 |
| 36 months | 0 | 0 | 1 | 10 | 0 | 0 | 1 | 10 | 30 | 30 | 0 | 0 | 2 | 20 | 0 | 0 | 2 | 4 | 19 | 19 |
| 42 months | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| 48 months | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |

| KEY | |
|-----------------------------|---|
| PBMC | Total # of samples represents # of PBMC aliquots per time point. Per protocol, PBMCs were to be aliquoted at 10x10 ⁶ or 5x10 ⁶ cells/mL, depending upon total cell count. However, actual concentrations per vial vary significantly. |
| Plasma | Total # of samples represents # of plasma aliquots per time point. Per protocol, plasma was to be aliquoted at 1.0 mL into each of 3 x 1.8 mL cryovials; only vial size was recorded. Actual samples stored in 1.8 mL and 0.5 mL cryovials. |
| Whole Blood - DNA | Total # samples represents # of whole blood samples collected for DNA extraction. Per protocol, one tube (6 mL) of whole blood was collected per subject; average DNA yield of 60 ug; split into 5 aliquots. |
| RNA | Total # samples represents # of RNA aliquots per timepoint. 6 mL whole blood collected for RNA extraction. Number of aliquots per time point varies depending upon yield. |
| Serum (Residual BAA) | Total # of samples represents # of autoantibody samples collected per time point. Following autoantibody testing, residual serum was stored for future study. Number and volume of stored serum aliquots per autoantibody collection varies. |
| Total # Subjects | Number of subjects who contributed to the samples collected at each time point. |